

# Maarten de Wit

## List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/6428712/publications.pdf](https://exaly.com/author-pdf/6428712/publications.pdf)

Version: 2025-02-01

135  
papers

16,068  
citations

50692

43  
h-index

12162

125  
g-index

140  
all docs

140  
docs citations

140  
times ranked

13869  
citing authors

#	ARTICLE	IF	CITATIONS
1	Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis. <i>RMD Open</i> , 2024, 10, e003548.	4.0	1
2	Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set. <i>Annals of the Rheumatic Diseases</i> , 2024, 83, 1288-1294.	1.5	0
3	Patient research partner involvement in rheumatology research: a systematic literature review informing the 2023 updated EULAR recommendations for the involvement of patient research partners. <i>Annals of the Rheumatic Diseases</i> , 2024, 83, 1268-1277.	1.5	1
4	EULAR recommendations for the involvement of patient research partners in rheumatology research: 2023 update. <i>Annals of the Rheumatic Diseases</i> , 2024, 83, 1443-1453.	1.5	4
5	GRAPPA 2023 Patient Research Partner (PRP) Network Update: Enhancing PRP Involvement Within GRAPPA. <i>Journal of Rheumatology</i> , 2024, 51, 9-11.	2.5	2
6	How to Involve Patients in GRAPPA Research as Partners. <i>Journal of Rheumatology</i> , 2024, 51, 61-64.	2.5	0
7	Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 773-787.	1.5	28
8	American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 74-80.	1.5	47
9	Matching researchersâ€™ needs and patientsâ€™ contributions: practical tips for meaningful patient engagement from the field of rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 312-315.	1.5	11
10	Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study. <i>RMD Open</i> , 2023, 9, e003157.	4.0	2
11	Series: Public engagement with research. Part 1: The fundamentals of public engagement with research. <i>European Journal of General Practice</i> , 2023, 29, .	1.9	6
12	Series: Public engagement with research. Part 4: Maximising the benefits of involving the public in research implementation. <i>European Journal of General Practice</i> , 2023, 29, .	1.9	4
13	Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2023, 15, .	3.8	6
14	Distinction and prognosis of early arthritis phenotypes: an analysis in three European cohorts. <i>RMD Open</i> , 2023, 9, e003611.	4.0	3
15	Involving patients as research partners in research in rheumatology: a literature review in 2023. <i>RMD Open</i> , 2023, 9, e003566.	4.0	4
16	Response to: â€˜Correspondence on â€˜EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 updateâ€™ by Fallon<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e174-e174.	1.5	15
17	Response to: â€˜Comment on: â€˜EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 updateâ€™ by Gossec<i>et al</i>â€™ by Wei<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e139-e139.	1.5	30
18	Response to: â€˜Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritisâ€™ by Bugatti<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e56-e56.	1.5	1

#	ARTICLE	IF	CITATIONS
19	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 780-785.	1.5	16
20	Identifying potential barriers and solutions to patient partner compensation (payment) in research. <i>Research Involvement and Engagement</i> , 2022, 8, .	2.8	22
21	Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: a cross-sectional analysis. <i>Joint Bone Spine</i> , 2022, , 105372.	2.1	3
22	Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence. <i>Rheumatology and Therapy</i> , 2022, 9, 803-821.	2.3	16
23	Exploring discordance between Health Literacy Questionnaire scores of people with RMDs and assessment by treating health professionals. <i>Rheumatology</i> , 2022, 62, 52-64.	2.0	5
24	Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to change in disease activity and impact. <i>Rheumatology</i> , 2022, 62, 98-107.	2.0	2
25	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	4.0	7
26	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	8.2	291
27	Unmet need for patient involvement in rheumatology registries and observational studies: a mixed methods study. <i>RMD Open</i> , 2022, 8, e002472.	4.0	3
28	Consideration of health literacy in patient information: a mixed-methods study of COVID-19 crisis communication in Dutch rheumatology. <i>BMC Rheumatology</i> , 2022, 6, .	2.3	4
29	Patient involvement in basic rheumatology research at Nijmegen: a three yearâ€™s responsive evaluation of added value, pitfalls and conditions for success. <i>BMC Rheumatology</i> , 2022, 6, .	2.3	10
30	Comparing the Patientâ€™Reported Physical Function Outcome Measures in a Realâ€™Life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 593-602.	3.1	11
31	Comment on: â€œIt canâ€™t be zero!â€™ difficulties in completing patient global assessment in rheumatoid arthritis: a mixed methods study: reply. <i>Rheumatology</i> , 2021, 60, e30-e31.	2.0	0
32	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	1.5	187
33	Addressing Health Literacy Needs in Rheumatology: Which Patient Health Literacy Profiles Need the Attention of Health Professionals?. <i>Arthritis Care and Research</i> , 2021, 73, 100-109.	3.1	28
34	Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 242-249.	1.5	7
35	Validity and reliability of the EULAR instrument RAID.7 as a tool to assess individual domains of impact of disease in rheumatoid arthritis: a cross-sectional study of 671 patients. <i>RMD Open</i> , 2021, 7, e001539.	4.0	12
36	Whatâ€™influences patientsâ€™ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , 2021, 60, 5292-5299.	2.0	5

#	ARTICLE	IF	CITATIONS
37	Experiences and perceptions of patients with psoriatic arthritis participating in a trial of faecal microbiota transplantation: a nested qualitative study. <i>BMJ Open</i> , 2021, 11, e039471.	2.0	11
38	Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1158-1167.	1.5	65
39	Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study. <i>Journal of Rheumatology</i> , 2021, 48, 1480-1487.	2.5	1
40	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606.	3.7	7
41	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	3.7	14
42	Researchers'™ perspectives on methodological challenges and outcomes selection in interventional studies targeting medication adherence in rheumatic diseases: an OMERACT-adherence study. <i>BMC Rheumatology</i> , 2021, 5, .	2.3	3
43	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, .	24.7	173
44	Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1108-1112.	3.7	8
45	Improving domain definition and outcome instrument selection: Lessons learned for OMERACT from imaging. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1125-1133.	3.7	17
46	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. <i>RMD Open</i> , 2021, 7, e001818.	4.0	4
47	Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique. <i>Arthritis Care and Research</i> , 2020, 72, 1410-1419.	3.1	20
48	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	3.1	46
49	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 12-22.	0.8	7
50	Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. <i>Journal of Rheumatology</i> , 2020, 47, 1565-1574.	2.5	16
51	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	4.0	44
52	Cost assessment of health interventions and diseases. <i>RMD Open</i> , 2020, 6, e001287.	4.0	23
53	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	1.5	11
54	Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 778-786.	1.5	106

#	ARTICLE	IF	CITATIONS
55	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	1.5	685
56	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 760-770.	1.5	209
57	Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1269-1276.	1.5	3
58	Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 744-759.	1.5	190
59	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 445-452.	1.5	46
60	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	1.5	1,957
61	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. <i>Joint Bone Spine</i> , 2020, 87, 449-454.	2.1	17
62	Health technology assessment: a framework. <i>RMD Open</i> , 2020, 6, e001289.	4.0	23
63	Steps in implementing a health economic evaluation. <i>RMD Open</i> , 2020, 6, e001288.	4.0	7
64	Patient engagement in health technology assessment (HTA) and the regulatory process: what about rheumatology?. <i>RMD Open</i> , 2020, 6, e001286.	4.0	9
65	Dual target strategy: a proposal to mitigate the risk of overtreatment and enhance patient satisfaction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e109-e109.	1.5	41
66	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1472-1479.	1.5	6
67	Addressing Challenges in Developing a Core Domain Set in Adherence Interventions in Rheumatology: A Report from the OMERACT-Adherence Group. <i>Journal of Rheumatology</i> , 2019, 46, 1202-1206.	2.5	4
68	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019, 46, 1159-1163.	2.5	10
69	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1028-1035.	2.5	68
70	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1053-1058.	2.5	9
71	Be an ambassador for change that you would like to see – a call to action to all stakeholders for co-creation in healthcare and medical research to improve quality of life of people with a neuromuscular disease. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, .	3.3	12
72	Practical guidance for engaging patients in health research, treatment guidelines and regulatory processes: results of an expert group meeting organized by the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Aging Clinical and Experimental Research</i> , 2019, 31, 905-915.	2.9	53

#	ARTICLE	IF	CITATIONS
73	Uptake of the OMERACT-OARSI Hip and Knee Osteoarthritis Core Outcome Set: Review of Randomized Controlled Trials from 1997 to 2017. <i>Journal of Rheumatology</i> , 2019, 46, 976-980.	2.5	26
74	Practical guidance for patient-centred health research. <i>Lancet, The</i> , 2019, 393, 1095-1096.	35.3	40
75	Pain Measurement in Rheumatic and Musculoskeletal Diseases: Where To Go from Here? Report from a Special Interest Group at OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1355-1359.	2.5	3
76	OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions. <i>Journal of Rheumatology</i> , 2019, 46, 1409-1414.	2.5	16
77	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	2.5	45
78	Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development. <i>Journal of Rheumatology</i> , 2019, 46, 1041-1046.	2.5	25
79	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019, 46, 1021-1027.	2.5	106
80	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1014-1020.	2.5	77
81	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.5	44
82	Unique role of rheumatology in establishing collaborative relationships in research. Past, present and future of patient engagement. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 293-296.	1.5	18
83	The Delphi methodâ€”more research please. <i>Journal of Clinical Epidemiology</i> , 2019, 106, 136-139.	4.0	80
84	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	1.5	62
85	The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee Osteoarthritis. <i>Journal of Rheumatology</i> , 2019, 46, 981-989.	2.5	106
86	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019, 71, 1556-1565.	3.1	51
87	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	2.5	14
88	Proceedings of the 2018 GRAPPA Collaborative Research Network Meeting. <i>Journal of Rheumatology</i> , 2019, 95, 11-19.	2.5	6
89	Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , 2018, 37, 1503-1510.	2.3	13
90	Preparing researchers for patient and public involvement in scientific research: Development of a hands-on learning approach through action research. <i>Health Expectations</i> , 2018, 21, 752-763.	3.1	38

#	ARTICLE	IF	CITATIONS
91	Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change. <i>Arthritis Care and Research</i> , 2018, 70, 369-378.	3.1	85
92	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	1.5	522
93	Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study. <i>Arthritis Care and Research</i> , 2018, 70, 1206-1217.	3.1	4
94	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	3.7	50
95	Development of a standard form for assessing research grant applications from the perspective of patients. <i>Research Involvement and Engagement</i> , 2018, 4, .	2.8	7
96	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	2.5	10
97	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.5	105
98	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	1.5	205
99	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	1.5	3,257
100	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	2.5	42
101	Emerging Guidelines for Patient Engagement in Research. <i>Value in Health</i> , 2017, 20, 481-486.	0.2	157
102	Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients. <i>Rheumatology</i> , 2017, 56, 1573-1578.	2.0	71
103	Determinants of Patient-Physician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. <i>Arthritis Care and Research</i> , 2017, 69, 1606-1611.	3.1	62
104	Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1889-1893.	2.5	15
105	Toward the Development of a Core Set of Outcome Domains to Assess Shared Decision-making Interventions in Rheumatology: Results from an OMERACT Delphi Survey and Consensus Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 1544-1550.	2.5	19
106	"They Are Talking About Me, but Not with Me": A Focus Group Study to Explore the Patient Perspective on Interprofessional Team Meetings in Primary Care. <i>Patient</i> , 2017, 10, 429-438.	2.5	27
107	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , 2016, 2, e000217.	4.0	36
108	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	1.5	191

#	ARTICLE	IF	CITATIONS
109	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	1.5	263
110	Fatigue in psoriatic arthritis—A cross-sectional study of 246 patients from 13 countries. <i>Joint Bone Spine</i> , 2016, 83, 439-443.	2.1	48
111	Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 490-498.	1.5	97
112	Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. <i>Journal of Rheumatology</i> , 2016, 43, 187-193.	2.5	50
113	Successful Stepwise Development of Patient Research Partnership: 14 Years' Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). <i>Patient</i> , 2016, 10, 141-152.	2.5	43
114	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 8-13.	1.5	231
115	Development of a Draft Core Set of Domains for Measuring Shared Decision Making in Osteoarthritis: An OMERACT Working Group on Shared Decision Making. <i>Journal of Rheumatology</i> , 2015, 42, 2442-2447.	2.5	20
116	Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1021-1026.	2.5	11
117	Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures. <i>Journal of Rheumatology</i> , 2015, 42, 2448-2459.	2.5	24
118	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. <i>Journal of Rheumatology</i> , 2014, 41, 1011-1015.	2.5	52
119	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	1.5	324
120	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	1.5	1,624
121	Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, .	4.5	37
122	Facilitators to implement standards of care for rheumatoid arthritis and osteoarthritis: the EUMUSC.NET project. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1545-1548.	1.5	8
123	Patient perspective in outcome measures developed by OMERACT. <i>Indian Journal of Rheumatology</i> , 2013, 8, S17-S22.	0.3	9
124	Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. <i>BMJ Open</i> , 2013, 3, e002241.	2.0	148
125	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	1.5	92
126	Facilitating and inhibiting factors for long-term involvement of patients at outcome conferences—lessons learnt from a decade of collaboration in OMERACT: a qualitative study. <i>BMJ Open</i> , 2013, 3, e003311.	2.0	29

#	ARTICLE	IF	CITATIONS
127	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	1.5	650
128	What have we learned from a decade of patient involvement in OMERACT and its effect on trial outcome assessments?. <i>Trials</i> , 2011, 12, .	2.2	2
129	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	1.5	1,675
130	Patients and professionals as research partners: Challenges, practicalities, and benefits. <i>Arthritis and Rheumatism</i> , 2006, 55, 676-680.	7.3	210
131	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 0, , jrheum.201679.	2.5	3
132	Proceedings of the 2021 GRAPPA-Collaborative Research Network (CRN) Meeting. <i>Journal of Rheumatology</i> , 0, , jrheum.211336.	2.5	0
133	Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Studenic <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 0, , ard-2022-223627.	1.5	0
134	EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 0, , ard-2023-224148.	1.5	33
135	Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual Meeting. <i>Journal of Rheumatology</i> , 0, , jrheum.2023-0534.	2.5	1